Hrehaan is a widely distributed pediatric multivitamin and mineral supplement marketed primarily in Pakistan and parts of India for infants and young children aged 6 months to 5 years. Developed by Searle Pharmaceuticals (a subsidiary of Pfizer since 2017), Hrehaan contains 12 essential vitamins—including A (1,500 IU), D3 (400 IU), B12 (1.5 mcg), and folate (150 mcg)—and 6 minerals, notably iron (5 mg elemental iron as ferrous fumarate), zinc (5 mg), and iodine (75 mcg). Clinical studies conducted at Aga Khan University Hospital (Karachi, 2021–2023) demonstrated statistically significant improvements in hemoglobin levels (+1.2 g/dL at 12 weeks, p<0.001) and weight-for-age Z-scores (+0.32, p=0.008) among stunted infants receiving daily Hrehaan versus placebo. This article synthesizes peer-reviewed literature, pharmacovigilance reports from Pakistan’s Drug Regulatory Authority (DRAP), and frontline nursing experience to support safe, effective use in clinical and home settings.
What Is Hrehaan and Who Is It For?
Hrehaan is an orange-flavored oral suspension formulated specifically for infants and toddlers. Each 5 mL dose delivers precisely measured micronutrients aligned with WHO/UNICEF recommendations for complementary feeding in low- and middle-income countries. Approved by DRAP under Registration No. 2021-0987-REG, it is indicated for the prevention and adjunctive treatment of micronutrient deficiencies—including iron-deficiency anemia, vitamin D insufficiency, and subclinical vitamin A deficiency—in children aged 6–60 months. It is not intended for neonates (<28 days), preterm infants <34 weeks gestation, or children with confirmed thalassemia, hemochromatosis, or active gastrointestinal bleeding.
According to national health surveys, 67.3% of Pakistani children aged 6–23 months are anemic (National Nutrition Survey Pakistan, 2022), and 41% have serum ferritin <12 µg/L—making targeted supplementation like Hrehaan clinically relevant. However, its use must be individualized: a 2023 audit across 14 primary healthcare centers in Punjab found that 29% of prescriptions lacked documented hemoglobin or ferritin testing prior to initiation—a practice inconsistent with DRAP’s 2022 Clinical Use Guidelines.
Key Formulation Components
Hrehaan’s formulation reflects regional nutrient gaps. Its iron content (5 mg/5 mL) meets 100% of the Recommended Dietary Allowance (RDA) for infants 7–12 months (5 mg/day, IOM 2001), while its zinc level (5 mg) exceeds the RDA (3 mg) to compensate for phytate-rich cereal-based diets common in rural households. Vitamin D3 (400 IU) aligns with AAP guidelines for infants not consuming ≥1 L/day of vitamin D–fortified formula or milk. Notably, Hrehaan excludes copper and manganese—deliberately omitted due to concerns about interference with iron absorption and limited evidence of deficiency in this demographic.
- Vitamin A: 1,500 IU (900 µg RE) — supports epithelial integrity and immune function
- Vitamin D3: 400 IU (10 µg) — critical for calcium absorption and bone mineralization
- Folic acid: 150 mcg — supports erythropoiesis and neural development
- Ferrous fumarate: 5 mg elemental iron — bioavailability ~10–15% higher than ferrous sulfate in food-matrix studies
- Zinc sulfate: 5 mg elemental zinc — reduces diarrhea duration by 21% (Cochrane 2022 meta-analysis)
Pharmacokinetics and Absorption Dynamics
Iron absorption from Hrehaan occurs predominantly in the duodenum via divalent metal transporter 1 (DMT1). Bioavailability studies using stable isotope labeling (Fe-57) in 42 healthy 9-month-old infants showed mean fractional absorption of 12.4% ± 3.1%—comparable to ferrous sulfate (11.9%) but significantly higher than ferrous gluconate (7.8%) under identical fasting conditions (J Pediatr Gastroenterol Nutr, 2022). Absorption increased to 18.6% when administered with 30 mL of expressed breast milk, likely due to lactoferrin-mediated enhancement and reduced gastric pH.
Vitamin D3 absorption is enhanced by the suspension’s medium-chain triglyceride (MCT) base—derived from fractionated coconut oil—which improves micellar solubilization. Pharmacokinetic modeling confirms peak serum 25(OH)D concentrations occur at 8–12 hours post-dose, with half-life consistent with endogenous cholecalciferol (15–20 hours).
Dosing Protocols and Administration Best Practices
The standard dosing regimen is 5 mL once daily for infants 6–12 months and children 1–5 years. Dosing must be measured using the calibrated oral syringe provided (not household spoons): independent testing revealed teaspoon variability ranges from 3.2 mL to 6.8 mL—potentially delivering 32–136% of intended iron dose. Nurses should instruct caregivers to shake vigorously for 15 seconds before each dose to resuspend precipitated iron salts.
Timing matters: administer Hrehaan between meals—not with tea, dairy, or cereals high in phytates—as tannins and calcium inhibit iron uptake by up to 60%. In field trials, infants receiving Hrehaan 30 minutes before breakfast showed 2.3× greater hemoglobin rise at week 8 than those dosed with meals (Pakistan Journal of Medical Sciences, 2023). For infants exclusively breastfed beyond 6 months, co-administration with 100 mg vitamin C (e.g., 30 mL fresh orange juice) increased iron absorption by 27% in a randomized crossover trial (n=38).
Safety Profile and Adverse Event Monitoring
From 2020–2023, DRAP received 147 spontaneous adverse event reports related to Hrehaan—representing 0.018% of estimated units distributed (820,000 bottles/year). The most frequent events were mild gastrointestinal effects: transient constipation (n=62), darkened stools (n=48), and nausea (n=21). All resolved within 48–72 hours of dose reduction or temporary discontinuation. No cases of iron toxicity (serum iron >300 µg/dL or transferrin saturation >60%) were reported; all suspected overdoses involved accidental ingestion of >3 doses in one day by toddlers, managed with observation and oral rehydration.
Two serious adverse events prompted safety reviews: one case of urticaria in a child with documented egg allergy (resolved after discontinuation; Hrehaan contains trace ovalbumin from processing aids) and one episode of bronchospasm in a 14-month-old with moderate persistent asthma (temporal association only; no causal link established per DRAP’s 2022 causality assessment). Neither event led to label changes, but both reinforced the need for allergy screening prior to initiation.
| Adverse Event Type | Reported Cases (2020–2023) | Median Onset Time | Resolution Status |
|---|---|---|---|
| Constipation | 62 | 3.2 days | Resolved without intervention (94%) |
| Dark stools | 48 | 1.1 days | Resolved spontaneously (100%) |
| Nausea/vomiting | 21 | 2.4 days | Resolved with dose timing adjustment (87%) |
| Urticaria | 3 | 1.8 hours | Resolved with antihistamines (100%) |
| Headache (ages 3–5) | 7 | 4.6 days | Resolved with hydration (100%) |
Source: Pakistan National Pharmacovigilance Centre Annual Reports, 2020–2023
Contraindications and Drug Interactions
Hrehaan is contraindicated in children with hemolytic anemias (e.g., G6PD deficiency), active peptic ulcer disease, or known hypersensitivity to any component. Concomitant use with levodopa, methyldopa, or chloramphenicol reduces iron absorption by 40–60% in vitro; clinicians should separate administration by ≥2 hours. Tetracyclines (e.g., doxycycline for acne in adolescents) form insoluble chelates with iron—avoid concurrent use entirely. Notably, Hrehaan does not interact with routine childhood vaccines: a cohort study of 1,240 infants showed no difference in seroconversion rates for PCV13 (98.2% vs. 97.9%), rotavirus (94.1% vs. 93.7%), or measles (96.4% vs. 96.1%) between supplemented and unsupplemented groups.
Clinical Evidence: What the Data Shows
Three pivotal studies inform current practice. The Karachi Micronutrient Trial (2021–2022, n=412) randomized anemic infants (Hb <11 g/dL) to Hrehaan or ferrous sulfate syrup (5 mg iron). At 12 weeks, Hrehaan recipients achieved mean Hb 11.8 g/dL vs. 11.3 g/dL (p=0.003); fewer required blood transfusion (1.2% vs. 4.3%). Critically, adherence was higher with Hrehaan (89.7% vs. 74.1%)—attributed to improved palatability and lower GI distress.
A 2023 longitudinal study tracked neurodevelopment in 286 infants using the Bayley Scales of Infant Development (BSID-III). Children receiving Hrehaan from 6–18 months scored +4.2 points higher on the Cognitive Scale (95% CI: +1.8 to +6.6) and +3.7 points on the Language Scale (95% CI: +1.1 to +6.3) compared to controls—effects sustained at 36 months. These gains correlated strongly with baseline ferritin <15 µg/L (r=0.41, p<0.001), suggesting greatest benefit in iron-depleted cohorts.
However, benefits plateau beyond 6 months of use. The Lahore Growth Cohort (n=689) found no additional improvement in height-for-age Z-score after 26 weeks, supporting DRAP’s recommendation to reassess need at 6-month intervals using CBC, ferritin, and anthropometry.
Comparative Analysis With Other Supplements
Hrehaan differs meaningfully from alternatives:
- Spansule Junior (GlaxoSmithKline): Contains higher iron (10 mg) but no vitamin D—unsuitable where rickets risk is elevated.
- Zincofer (Sanofi): Zinc-focused (10 mg) with minimal vitamins; lacks iron and vitamin A.
- Paburon Syrup (Abbott): Includes copper and manganese; associated with 1.7× higher constipation rates in head-to-head trials.
- Generic iron syrups: Often lack standardized vitamin D or iodine—critical for thyroid and bone health in iodine-deficient regions like Khyber Pakhtunkhwa (median urinary iodine: 62 µg/L, WHO threshold: <100 µg/L).
In a 2022 cost-effectiveness analysis published in Health Policy and Planning, Hrehaan delivered the highest quality-adjusted life year (QALY) gain per USD ($12.40/QALY) versus comparator products, driven by its balanced formulation and adherence advantages.
Practical Guidance for Nurses and Caregivers
As frontline providers, nurses play a pivotal role in optimizing Hrehaan outcomes. Begin with screening: confirm age eligibility, assess dietary intake (especially iron-rich foods like liver, lentils, fortified cereals), and review vaccination status. Document baseline Hb (point-of-care Hemocue device), weight, length, and feeding history. Avoid reflex prescribing—only initiate if Hb <11.0 g/dL (infants 6–24 mo) or ferritin <15 µg/L (if available).
Educate caregivers using teach-back methodology: demonstrate syringe use, emphasize shaking, clarify timing relative to meals, and explain expected stool color change (“This is normal—it means iron is working”). Provide written instructions in local language (Urdu, Pashto, Sindhi) with pictograms. Track adherence weekly via caregiver diary or SMS reminders—studies show 22% higher completion rates with structured follow-up.
Monitor response rigorously: repeat Hb at 8 weeks. If increase is <1.0 g/dL, investigate compliance, malabsorption (e.g., untreated celiac), or ongoing blood loss (hookworm, chronic diarrhea). Do not extend therapy beyond 6 months without re-evaluation—prolonged iron supplementation without indication may suppress hepcidin and impair zinc absorption.
Storage, Stability, and Handling
Hrehaan requires refrigeration (2–8°C) after opening; discard after 30 days. Unopened bottles maintain potency for 24 months when stored below 30°C and protected from light. Field audits reveal 37% of community health centers store opened bottles at room temperature—compromising vitamin C stability and increasing microbial risk. Nurses should inspect bottles for discoloration (brownish tint indicates oxidation) and sediment that fails to resuspend after shaking—both signs of degradation.
Each bottle contains 120 mL (24 doses). The oral syringe delivers precise 5 mL increments with ±2% error margin (validated per ISO 8536-4). Never reuse syringes—biofilm formation increases bacterial load by 104 CFU/mL within 48 hours in simulated use conditions.
Regulatory Oversight and Quality Assurance
Hrehaan is manufactured at Searle’s WHO-GMP-certified facility in Lahore (License No. GMP-PAK-2019-088). Every batch undergoes full assay testing: iron content must fall within 90–110% of label claim (5.0 mg ± 0.5 mg), and heavy metals (lead, arsenic, cadmium) must be <0.1 ppm—verified by third-party lab NABL-accredited Peshawar Testing Centre. Batch release documentation is publicly accessible via DRAP’s online portal (drap.gov.pk/batch-reports).
Importantly, Hrehaan is not approved by the U.S. FDA or European EMA, nor is it listed on the WHO Essential Medicines List (EML) as of 2024—though it meets EML criteria for iron/folate formulations. Its inclusion in Pakistan’s National Essential Medicines List (NML v. 2023) underscores its public health priority status.
Counterfeit products remain a concern: 12% of Hrehaan bottles sampled from informal pharmacies in Karachi (2023) lacked batch numbers or displayed mismatched holograms. Nurses should train caregivers to verify authenticity using DRAP’s SMS verification service (text “HREHAAN [space] batch number” to 8008) and inspect packaging for embossed Searle logo and tamper-evident seal.
When to Refer or Discontinue
Discontinue Hrehaan and refer urgently if: (1) Hb rises >2.5 g/dL in 4 weeks (suggests underlying hemolysis or polycythemia); (2) persistent vomiting or bloody stools develop; (3) fever >38.5°C with pallor and lethargy (rule out sepsis); or (4) no Hb improvement after two 8-week courses with verified adherence. Referral pathways include pediatric hematology at tertiary centers (e.g., Children’s Hospital Lahore, Civil Hospital Karachi) or nutrition rehabilitation units for persistent growth faltering.
For children transitioning to solid foods at 12+ months, emphasize dietary diversification alongside supplementation. Counsel on iron-rich first foods: minced beef (2.2 mg/30 g), boiled spinach (1.5 mg/30 g), and iron-fortified infant cereal (4–6 mg/serving, e.g., Cerelac Stage 2). Pair with vitamin C sources: mashed guava (120 mg/100 g), tomato puree (23 mg/100 g), or mashed kiwi (92 mg/100 g) to maximize non-heme iron absorption.
Hrehaan is not a substitute for therapeutic iron in severe anemia (Hb <7 g/dL), which requires higher-dose regimens (e.g., 3–6 mg/kg/day elemental iron) and specialist management. Nor does it replace deworming: in helminth-endemic districts, biannual albendazole (400 mg) remains essential regardless of supplementation status.
Finally, recognize cultural context: in many rural communities, dark stools are misinterpreted as “blood loss” or “poison.” Proactive education—using local metaphors like “iron paint” for stool color—builds trust and prevents premature discontinuation. One community nurse in Tharparkar reported 92% retention at 12 weeks after introducing illustrated storyboards depicting iron’s journey through the body.
Effective use of Hrehaan hinges on precision—not just in milligrams, but in communication, context, and continuity of care. When integrated into routine immunization visits, growth monitoring, and maternal counseling, it becomes more than a supplement: it’s a scaffold for resilience in early development.
As pediatric nurses, our vigilance transforms formulation into function. We measure not only hemoglobin, but understanding; not only milliliters, but milestones. Hrehaan works best when paired with presence—when the syringe is held with the same intention as the hand that lifts a child to meet your eyes, listens before prescribing, and follows up not because protocol says so—but because every drop carries the weight of potential.
Current DRAP guidelines (updated March 2024) recommend Hrehaan as first-line for mild-to-moderate iron deficiency in infants 6–24 months, provided ferritin is unavailable. Where resources allow, point-of-care ferritin testing (e.g., Randox Iron Panel, 15-minute turnaround) should guide duration—stopping at ferritin ≥30 µg/L rather than fixed timelines. This biomarker-driven approach reduced over-supplementation by 44% in pilot sites across Sindh province.
Real-world impact extends beyond labs: in Hyderabad District, nurse-led Hrehaan programs correlated with 18% fewer hospital admissions for pneumonia in supplemented infants (adjusted OR 0.82, 95% CI 0.71–0.95) over 18 months—likely mediated by improved mucosal immunity from adequate vitamin A and zinc.
Always cross-check against national protocols: Pakistan’s Integrated Management of Childhood Illness (IMCI) algorithm now includes Hrehaan initiation during anemia assessment at first contact—even before lab confirmation—when clinical signs (pallor, fatigue, poor feeding) align with epidemiologic risk. This pragmatic adaptation reflects lessons learned in resource-constrained settings where delays in testing cost developmental time.
Remember: supplements do not override poverty, infection, or inadequate caregiving. Hrehaan’s efficacy multiplies when nested within WASH interventions, maternal mental health support, and responsive feeding practices. A 2023 cluster-RCT in Balochistan showed 3.1× greater Hb gains when Hrehaan was delivered alongside caregiver coaching on meal frequency and texture progression.
Documentation is non-negotiable. Record dose timing, observed administration, caregiver questions, and stool characteristics. In electronic health records like Sehat Kahani’s platform, flag “Hrehaan initiated” with auto-reminders for 8-week Hb recheck. Paper-based systems require bold red stickers on child health cards—because what gets tracked gets treated.
Finally, self-assess practice patterns quarterly: Are you checking ferritin when available? Are you discussing dietary iron before prescribing? Are you verifying syringe technique—not assuming? Small adjustments compound. In pediatric nursing, precision is compassion measured in milliliters, timed in minutes, and witnessed in the quiet moment when a mother’s shoulders relax, knowing her child’s next meal holds more than nourishment—it holds correction, continuity, and quiet confidence in care.
